Abstract
Cefiderocol is a new siderophore cephalosporin which represents a later option for the treatment of multi-drug–resistant, gram-negative infections, especially in the case of resistance to the new combinations of β-lactam and β-lactamase. Real-life data on the use of cefiderocol for the treatment of severe multi-drug–resistant, non-fermenting, gram-negative bacilli (NFGNB) infections are scarce.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
